News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,851 Results
Type
Article (13846)
Company Profile (101)
Press Release (252904)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88126)
Career Advice (465)
Deals (15356)
Drug Delivery (67)
Drug Development (36641)
Employer Resources (49)
FDA (6310)
Job Trends (6205)
News (150368)
Policy (14056)
Tag
Academia (442)
Accelerated approval (2)
Adcomms (6)
Allergies (38)
Alliances (23249)
ALS (39)
Alzheimer's disease (397)
Antibody-drug conjugate (ADC) (46)
Approvals (6349)
Artificial intelligence (116)
Autoimmune disease (9)
Automation (5)
Bankruptcy (149)
Best Places to Work (4371)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (40)
Bladder cancer (23)
Brain cancer (16)
Breast cancer (84)
Cancer (666)
Cardiovascular disease (74)
Career advice (409)
Career pathing (12)
CAR-T (24)
Cell therapy (92)
Cervical cancer (4)
Clinical research (31024)
Collaboration (372)
Compensation (168)
Complete response letters (17)
COVID-19 (761)
CRISPR (23)
C-suite (135)
Cystic fibrosis (39)
Data (721)
Denatured (15)
Depression (10)
Diabetes (84)
Diagnostics (1333)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (62)
Drug pricing (71)
Drug shortages (12)
Duchenne muscular dystrophy (42)
Earnings (32493)
Editorial (14)
Employer branding (4)
Employer resources (43)
Events (37716)
Executive appointments (415)
FDA (6816)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (230)
Gene editing (41)
Generative AI (9)
Gene therapy (106)
GLP-1 (355)
Government (1309)
Grass and pollen (3)
Guidances (74)
Healthcare (3581)
Huntington's disease (4)
IgA nephropathy (13)
Immunology and inflammation (38)
Indications (14)
Infectious disease (796)
Inflammatory bowel disease (58)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (50)
Interviews (59)
IPO (5897)
IRA (29)
Job creations (2052)
Job search strategy (373)
Kidney cancer (6)
Labor market (14)
Layoffs (184)
Leadership (4)
Legal (3436)
Liver cancer (19)
Lung cancer (88)
Lymphoma (60)
Machine learning (4)
Management (16)
Manufacturing (177)
MASH (37)
Medical device (1283)
Medtech (1285)
Mergers & acquisitions (9683)
Metabolic disorders (275)
Multiple sclerosis (23)
NASH (14)
Neurodegenerative disease (29)
Neuropsychiatric disorders (9)
Neuroscience (601)
NextGen: Class of 2025 (1590)
Non-profit (597)
Now hiring (8)
Obesity (155)
Opinion (119)
Ovarian cancer (22)
Pain (58)
Pancreatic cancer (17)
Parkinson's disease (48)
Partnered (7)
Patents (131)
Patient recruitment (30)
Peanut (10)
People (29033)
Pharmaceutical (64)
Pharmacy benefit managers (13)
Phase I (8077)
Phase II (13123)
Phase III (11781)
Pipeline (585)
Policy (76)
Postmarket research (1401)
Preclinical (3241)
Press Release (25)
Prostate cancer (49)
Psychedelics (8)
Radiopharmaceuticals (121)
Rare diseases (176)
Real estate (2644)
Recruiting (17)
Regulatory (10168)
Reports (14)
Research institute (567)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (3)
RSV (8)
Schizophrenia (43)
Series A (40)
Series B (16)
Service/supplier (3)
Sickle cell disease (32)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1632)
State (2)
Stomach cancer (3)
Supply chain (32)
Tariffs (39)
The Weekly (30)
Vaccines (161)
Venture capitalists (14)
Weight loss (101)
Women's health (8)
Worklife (4)
Date
Today (72)
Last 7 days (316)
Last 30 days (1198)
Last 365 days (11621)
2025 (4535)
2024 (12513)
2023 (14262)
2022 (19576)
2021 (20099)
2020 (19057)
2019 (14909)
2018 (11725)
2017 (13893)
2016 (13134)
2015 (15477)
2014 (12421)
2013 (10594)
2012 (11398)
2011 (11926)
2010 (10891)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (59)
Arkansas (3)
Asia (20190)
Australia (2619)
California (1909)
Canada (975)
China (258)
Colorado (74)
Connecticut (83)
Delaware (65)
Europe (39626)
Florida (368)
Georgia (42)
Idaho (9)
Illinois (213)
India (16)
Indiana (142)
Iowa (1)
Japan (105)
Kansas (61)
Kentucky (13)
Louisiana (2)
Maine (2)
Maryland (277)
Massachusetts (1645)
Michigan (32)
Minnesota (105)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (9)
New Hampshire (6)
New Jersey (830)
New Mexico (7)
New York (560)
North Carolina (414)
North Dakota (2)
Northern California (791)
Ohio (51)
Oklahoma (4)
Oregon (16)
Pennsylvania (480)
Puerto Rico (8)
Rhode Island (10)
South America (503)
South Carolina (3)
Southern California (806)
Tennessee (36)
Texas (255)
United States (7923)
Utah (36)
Virginia (86)
Washington D.C. (32)
Washington State (129)
Wisconsin (21)
266,851 Results for "serenity pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
March 10, 2025
·
12 min read
Press Releases
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
March 12, 2025
·
10 min read
BioMidwest
Beltone Unveils a New Generation of Hearing Solutions with Beltone Serene
Beltone, named one of America’s Best Retailers and Customer Service for Hearing Care by Newsweek, announced its latest innovation in hearing care – the new Beltone Serene™ hearing aid.
September 28, 2023
·
4 min read
Business
Acerus Announces Amendment to Promissory Note Due to Former Serenity Shareholders
Acerus Pharmaceuticals Corporation today announced that it has amended the promissory note (the “ Note ”) in the amount of US$4.91 million related to the up-front fee owed to former Serenity Pharmaceuticals LLC (“Serenity”) securityholders.
October 3, 2022
·
3 min read
Press Releases
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
September 5, 2024
·
9 min read
Biotech Beach
Quantgene Launches Serenity Complete, the Next Generation Executive Physical
Quantgene, a Santa Monica, CA-based biotechnology, cloud and AI company, that focuses on precision medicine, introduced Serenity Complete, a new preventive health tool developed to help attract and retain top-tier talent.
November 14, 2022
·
5 min read
Business
Acerus Announces Amendment and Restatement of the Promissory Note Related to the Up-Front Fee Payable to Former Serenity Securityholders
Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCD) today announced that it has entered into an amended and restated promissory note (the “ A&R Note ”) covering the up-front fee owed to former Serenity Pharmaceuticals LLC (“ Serenity ”) securityholders.
June 7, 2022
·
2 min read
Deals
Acerus Announces Definitive Agreement to Acquire Serenity LLC and the Global Rights to Noctiva™
Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into a definitive agreement (the “Definitive Agreement”) to indirectly acquire Serenity LLC (“Serenity”) and the global rights to its Noctiva brand in a combined cash and stock transaction.
February 28, 2022
·
15 min read
Deals
Serenity Bioworks Acquires DC-TAB for Lupus Nephritis
Serenity Bioworks announces today it has completed the acquisition of DC-TAB, a recombinant human HspB5 that was previously in clinical development for relapse-remitting multiple sclerosis.
April 27, 2022
·
2 min read
Deals
Acerus Announces Closing of Acquisition of Serenity Pharmaceuticals LLC and Acquisition of Global Rights to Noctiva™Conference Call to be Held on March 9, 2022 at 8:30am ET to Discuss Transaction
Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced the closing of its previously-announced acquisition of Serenity Pharmaceuticals LLC (“Serenity”), including the global rights to its Noctiva™ brand.
March 7, 2022
·
6 min read
1 of 26,686
Next
